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Abstract Voltage-gated Na? channels (VGSCs) are
heteromeric membrane protein complexes containing pore-
forming a subunits and smaller, non-pore-forming b sub-
units. VGSCs are classically expressed in excitable cells,
including neurons and muscle cells, where they mediate
action potential firing, neurite outgrowth, pathfinding, and
migration. VGSCs are also expressed in metastatic cells
from a number of cancers. The Nav1.5 a subunit (encoded
by SCN5A) is expressed in breast cancer (BCa) cell lines,
where it enhances migration and invasion. We studied the
expression of SCN5A in BCa array data, and tested the
effect of the VGSC-blocking anticonvulsant phenytoin
(5,5-diphenylhydantoin) on Na? current, migration, and
invasion in BCa cells. SCN5A was up-regulated in BCa
samples in several datasets, and was more highly expressed
in samples from patients who had a recurrence, metastasis,
or died within 5 years. SCN5A was also overexpressed as
an outlier in a subset of samples, and associated with
increased odds of developing metastasis. Phenytoin inhib-
ited transient and persistent Na? current recorded from
strongly metastatic MDA-MB-231 cells, and this effect
was more potent at depolarized holding voltages. It may
thus be an effective VGSC-blocking drug in cancer cells,
which typically have depolarized membrane potentials. At
a concentration within the therapeutic range used to treat
epilepsy, phenytoin significantly inhibited the migration
and invasion of MDA-MB-231 cells, but had no effect on
weakly metastatic MCF-7 cells, which do not express
Na? currents. We conclude that phenytoin suppresses Na?
current in VGSC-expressing metastatic BCa cells, thus
inhibiting VGSC-dependent migration and invasion.
Together, our data support the hypothesis that SCN5A is
up-regulated in BCa, favoring an invasive/metastatic phe-
notype. We therefore propose that repurposing existing
VGSC-blocking therapeutic drugs should be further
investigated as a potential new strategy to improve patient
outcomes in metastatic BCa.
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Introduction
Breast cancer (BCa) is the most common cancer in women,
and the leading cause of female cancer-related deaths
worldwide [1]. Metastasis is the main cause of mortality
and is therefore a critical therapeutic target [2]. Treatment
options currently available to patients with metastatic BCa
are largely limited to palliation [3]. Thus, there is an urgent
need to identify new molecular targets and adjuvant ther-
apies with curative intent.
Voltage-gated Na? channels (VGSCs) are heteromeric
membrane protein complexes composed of one pore-
forming a subunit and smaller b subunits [4]. Inward flow
of Na? through VGSCs is responsible for the depolarizing
phase of action potentials in neurons and muscle cells [5].
There are nine a subunits (Nav1.1–Nav1.9) and four
b subunits (b1–b4) [4]. The b subunits contain an extra-
cellular immunoglobulin loop [6]. While they do not form
the ion conducting pore, they modulate channel gating, and
are members of the immunoglobulin superfamily of cell
adhesion molecules (CAMs) [7]. VGSCs play a key role in
organogenesis of the developing central nervous system
[8]. VGSC a and b subunits function within complexes in
neurons to regulate electrical excitability, neurite out-
growth, pathfinding, and migration [9–11].
VGSCs are widely expressed in metastatic cells from a
number of cancers, including BCa (reviewed in [8]). For
example, SCN5A (encoding Nav1.5), SCN8A (encoding
Nav1.6), and SCN9A (encoding Nav1.7) mRNAs have been
detected in BCa cell lines [12]. Of these, a neonatal splice
variant of SCN5A is most abundant, and its mRNA is
*1,800-fold higher in strongly metastatic MDA-MB-231
cells than weakly metastatic MCF-7 cells [12]. Na? cur-
rents have been recorded in MDA-MB-231 cells, but are
absent in weakly metastatic MCF-7 cells [12, 13]. Neonatal
SCN5A mRNA expression in BCa biopsies correlates with
occurrence of lymph node metastasis [12]. Suppression of
Nav1.5 in MDA-MB-231 cells, either with the pore-
blocking tetrodotoxin (TTX), function-blocking antibodies,
or with siRNA, inhibits cellular behaviors associated with
metastasis, including detachment, migration, galvanotaxis,
and invasion [12–15]. Na? current carried by Nav1.5
enhances the cells’ invasiveness by promoting cysteine
cathepsin activity in caveolae [16, 17]. In contrast to
Nav1.5, the VGSC b1 subunit functions as a CAM in BCa
cells, enhancing adhesion [18]. Thus, VGSC a and b sub-
units appear to play dynamic roles in regulating cell
adhesion, migration, and invasion in BCa.
Phenytoin (5,5-diphenylhydantoin), a class 1b antiar-
rhythmic agent and widely used antiepileptic drug, is a
potent blocker of VGSCs (IC50 *10 lM) [19, 20]. It also
inhibits delayed rectifier human Ether-a`-go-go-related gene
(HERG) K? channels at significantly higher concentrations
(IC50 [ 300 lM) [21]. The affinity of VGSCs for phenyt-
oin is increased when they are in their inactivated state,
following sustained membrane depolarization or high fre-
quency channel activation, e.g., during action potential
firing in neurons [20]. Phenytoin inhibits prostate-specific
antigen (PSA) and interleukin-6 (IL-6) secretion, and
migration in prostate cancer cells [22, 23]. It also sup-
presses endocytosis in small cell lung cancer cells [20, 24].
However, the effect of phenytoin on VGSC currents and
metastatic cell behavior in BCa cells is unknown.
Our aims here were to (1) study the expression of
SCN5A in published BCa array data and (2) assess the
effect of phenytoin on Na? current, migration, and invasion
in BCa cells. We demonstrate that SCN5A is up-regulated
in BCa samples in several datasets, and associates with
poor prognosis. In addition, phenytoin inhibits Na? current,
migration, and invasion in metastatic BCa cells in vitro.
We propose that VGSCs may be a promising target for
therapeutic intervention in BCa using existing VGSC-
inhibiting drugs. Furthermore, phenytoin, as a widely used
FDA-approved oral anticonvulsant, should be further
studied as a potential, cost-effective, new treatment
approach.
Methods
In silico analysis
SCN5A expression in BCa microarrays was studied using
the web-based Oncomine database, as described previously
[25–27]. Normalization and statistical analysis were per-
formed in Oncomine using the standard settings: for each
array, data were log2-transformed, median centered, and
standard deviation normalized to one [25]. Fold changes
\1.3-fold were not considered significant because such
small changes are often not reproducible by quantitative
PCR validation [28–30]. Cancer outlier profile analysis
(COPA) was used to evaluate SCN5A outlier expression in
a subset of BCa samples [31]. Outlier expression was
defined as being in the top 10 % of COPA scores at any of
three percentile cutoffs (75th, 90th, and 95th). Where
Breast Cancer Res Treat
123
applicable, REMARK reporting criteria have been used
[32]. Patients, specimen characteristics and assay methods
are detailed in the reference cited for each dataset, and at
www.oncomine.org.
Cell culture
MCF-7 and MDA-MB-231 cells were grown in Dulbecco’s
modified eagle medium supplemented with 5 % fetal
bovine serum and 4 mM L-glutamine [12]. Cells were
confirmed to be mycoplasma-free by 40,6-diamidino-2-
phenylindole (DAPI) method [33]. Molecular identity was
confirmed by short tandem repeat analysis [34].
Immunocytochemistry, confocal microscopy,
and image analysis
Immunocytochemistry and confocal microscopy were
performed as in Refs. [9, 10]. Samples were labeled with a
monoclonal pan-VGSC a subunit antibody (1:100; Sigma),
polyclonal anti-b1 antibody (1:2,000) [35] or polyclonal
anti-GM130 antibody (1:1,500; Proteintech), Alexa Fluor-
conjugated phalloidin (1:40; Molecular Probes), and DAPI.
Images were processed and analyzed using ImageJ soft-
ware (NIH). The intensity profiles of VGSC a subunit and
phalloidin were determined using the ‘‘straight line profile’’
function drawn across lamellipodia into the cell body, as in
Refs. [36, 37]. For both channels, peak signal intensity in
lamellipodia (defined as the peak in phalloidin labeling)
was expressed as a ratio of the mean signal intensity
5–10 lm inside the plasma membrane. Measurements
(3 per cell) were taken from C12 cells per line.
Electrophysiology
The whole-cell patch clamp technique was used to record
membrane Na? currents from cells grown on glass cover-
slips [18]. Voltage-clamp recordings were made using a
Multiclamp 700B amplifier (Molecular Devices) compen-
sating for series resistance by 40–60 %. Currents were
digitized using a Digidata 1440A interface (Molecular
Devices), low-pass filtered at 10 kHz, sampled at 50 kHz,
and analyzed using pCLAMP 10.3 software (Molecular
Devices). Linear components of leak were subtracted using
a P/6 protocol [38]. Data manipulation and curve fitting
were performed as before [9].
Pharmacology
Phenytoin sodium salt (Sigma) was prepared as a 180 mM
stock dissolved in 75 mM NaOH. It was frozen in aliquots,
then thawed and diluted in culture medium to 5–200 lM,
as required. Control cells were treated with the final
working concentration of NaOH (2–83 lM). In assays that
exceeded 24 h, treatments were replaced daily.
Viability
The cytotoxicity of phenytoin was determined using a
trypan blue exclusion assay [39]. Cells (5 9 104) were
plated in 35 mm dishes. The next day, dishes were treated
each with phenytoin or vehicle. After 24 h, the number of
live versus dead cells was determined from 20 fields of
view per dish. Results were compiled from three experi-
mental repeats.
Proliferation
Cells (3 9 104 per well) were seeded in 12-well plates. The
following day, triplicate wells were treated each with
phenytoin or vehicle for 24 h. The number of cells per well
was determined using the colorimetric 3-[4,5-dimethylthi-
azol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay
[40]. Results were compiled as the mean of three repeats.
Motility
Cellular motility was determined using a wound healing
assay, as described previously [23]. Cells (2 9 105) were
seeded in 35 mm dishes. The following day, three wounds
were made per dish using a P1000 pipette tip. Dishes were
rinsed once in fresh medium, and wound widths were
immediately measured (W0) using an inverted microscope
with graticule at 45 fixed points per dish (pre-labeled on the
underside of the dish with a pen). Dishes were then treated
with phenytoin or vehicle for 24 h and the same sites were
subsequently re-measured (Wt). For each site, a migration
index (MI) was calculated as MI = 1 - (Wt/W0). Means
were compiled from three repeat experiments, giving at
least 135 data points for analysis.
Invasion
Cell culture inserts for 24-well plates, with 8 lm pores, were
coated with extracellular matrix gel (Sigma). Cells
(5 9 104/ml) were plated in triplicate in a 0.1–1 % fetal
bovine serum chemotactic gradient and incubated with
phenytoin (50 lM) or vehicle for 48 h. The number of
invaded cells was determined using the MTT assay [12, 40].
Results were compiled as the mean of three repeats.
Data analysis
Data are presented as mean and SEM unless stated other-
wise. Statistical analysis was performed using GraphPad
Prism 5.0d. Normal distribution was determined using
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D’Agostino–Pearson omnibus test. Pairwise statistical
significance was determined with t tests, or Mann–Whitney
tests. Multiple comparisons were made using ANOVA and
Tukey post hoc tests, or Kruskal–Wallis with Dunns tests,
as appropriate. P values computed by Oncomine were
corrected for multiple comparisons by Bonferroni method
[25]. Predictive value of SCN5A was assessed using
receiver operating characteristic (ROC) curves. Kaplan–
Meier curves for overall survival were compared by log-
rank tests. Percent survival and hazard ratios are presented
with 95 % confidence intervals. Results were considered
significant at P \ 0.05 (*).
Results
SCN5A is expressed in patient BCa samples and is
predictive of poor prognosis
Nav1.5 (in its neonatal splice form) is present in BCa
biopsies, correlating with lymph node metastasis [12].
Nav1.5 is also expressed in MDA-MB-231 cells, where it
potentiates invasion and migration [12, 13, 15]. In order to
extend these observations to clinically relevant datasets, we
used the Oncomine database to compare the expression of
SCN5A in normal breast and BCa samples across multiple
microarrays [25]. SCN5A was expressed at significantly
higher levels in BCa (including ductal carcinoma in situ,
and invasive, ductal and metastatic BCa), compared with
normal breast tissue, in three out of seven datasets for
which differential data were available [1.5-fold, P \ 0.001,
[41] and The Cancer Genome Atlas (TCGA) dataset1; and
3.6-fold, P \ 0.05 [42] (Fig. 1a)]. There was no relation-
ship between SCN5A expression and estrogen receptor
(ER), progesterone receptor (PR), or human epidermal
growth factor 2 (HER2) status (Table 1).
We next studied the prognostic value of SCN5A expres-
sion. SCN5A was more highly expressed in tumor samples
from patients who subsequently developed metastases than
from those who did not within 1 year (P \ 0.05), 3 years
(P \ 0.01), and 5 years (P \ 0.01) [43]. However, the up-
regulation of SCN5A (1.3-fold) was at the limit of signifi-
cance [28–30]. Nonetheless, ROC analysis revealed that
SCN5A expression was effective at predicting metastasis
[area under the curve (AUC) = 0.63 ± 0.06; P \ 0.05;
Fig. 1b]. SCN5A was more highly expressed in those who
experienced recurrence within 5 years than from those who
did not (4.1-fold; P \ 0.05; Fig. 1c [44]). In addition,
SCN5A expression was higher in patients who were dead at
5 years (3.6-fold, P \ 0.05, Fig. 1d; TCGA dataset). High
SCN5A expression (cut-off at 60th percentile) associated
with reduced survival (overall survival at 60 months: 45.4 %
[25.3–63.5] for ‘‘low’’ SCN5A expression, and 18.5 %
[4.3–40.0] for ‘‘high’’ SCN5A expression; hazard ratio = 2.1
[0.93–4.84]), although this was not quite statistically sig-
nificant (P = 0.07; log-rank test; Fig. 1e [45]).
We next used COPA in Oncomine to investigate whe-
ther SCN5A, similar to other heterogeneously activated
oncogenes [31], was expressed as an outlier. An outlier
profile occurs when a gene is highly expressed in a fraction
of samples in the total population. SCN5A was overex-
pressed in the top 10 % of outliers at the 75th, 90th, and
95th percentiles, across five datasets (mean COPA score:
12.4 ± 4.3; Fig. 2a; Table 2). SCN5A overexpression as an
outlier (cut-off at 90th percentile) in the primary tumor was
associated with developing metastasis within 5 years [odds
ratio = 3.2 (1.1–9.4); P \ 0.05; Fig. 2b) [43]. In summary,
SCN5A expression is higher in BCa than normal breast
across several datasets in Oncomine, and is higher in BCa
samples from patients who developed metastasis, recur-
rence, or who died within 5 years. Furthermore, SCN5A is
overexpressed as an outlier in a subset of samples, and
associates with increased odds of developing metastasis.
VGSC a and b subunits are expressed in BCa cell lines
Strongly metastatic MDA-MB-231 cells express signifi-
cantly more neonatal Nav1.5 protein than weakly meta-
static MCF-7 cells [12]. By contrast, b1 is more highly
expressed in MCF-7 cells than MDA-MB-231 cells [18].
Here, we studied the subcellular distribution of VGSC a
and b1 subunits in MDA-MB-231 and MCF-7 cells by
confocal immunocytochemistry. Given that b1 can modu-
late Na? current carried by Nav1.5 [18], and that b1-
mediated process extension in neurons requires Na? cur-
rent [9], we hypothesized that a and b1 subunits colocalize
at the plasma membrane of BCa cells, as in neurons [9].
We used a pan-specific a subunit antibody, which will
detect not only Nav1.5 but also Nav1.6 and Nav1.7, which
have also been detected in these cell lines at mRNA level
[12]. We found that in both MCF-7 and MDA-MB-231
cells, a subunits were expressed throughout the cytoplasm,
and on perinuclear internal membranes, colocalizing with
b1 and the Golgi marker GM130 (Fig. 3a, b, arrowheads).
This pattern of expression is consistent with previous
reports from us and other groups showing perinuclear
VGSC expression inside neurons, HEK-293, and cancer
cells [15, 17, 36, 46, 47]. Importantly, a and b1 were also
colocalized along lamellipodia, defined by phalloidin
labeling of F-actin (Fig. 3a, arrows). Line profiles drawn
across lamellipodia revealed that a subunits were highly
expressed at the lamellipodial plasma membrane of MDA-
MB-231 cells, colocalizing with a peak in phalloidin1 http://tcga-data.nci.nih.gov/tcga/.
Breast Cancer Res Treat
123
staining, but less so in MCF-7 cells (Fig. 3c, d). The ratio
of lamellipodial/cell body staining was significantly higher
in MDA-MB-231 than MCF-7 cells (P \ 0.001; Fig. 3e).
This suggests that a subunits are more highly expressed at
the lamellipodia of MDA-MB-231 cells than MCF-7 cells.
Given that the neonatal Nav1.5 splice variant is more
highly expressed in MDA-MB-231 cells than MCF-7 cells
[12], the a subunit immunoreactivity in MCF-7 cells may
represent other variant(s) of Nav1.5 that have impaired
conduction [48], or other subtypes, e.g., Nav1.6 or Nav1.7
[12]. In summary, the arrangement of a subunits and b1 at
lamellipodia is consistent with their functioning within
complexes in these regions to regulate adhesion and
migration.
Phenytoin inhibits Na? currents in MDA-MB-231 cells
In order to explore the therapeutic potential of Nav1.5
expression in BCa, we next tested the effect of a widely
used VGSC-blocking anticonvulsant drug, phenytoin
(50 lM), on Na? current in BCa cells, using whole-cell
patch clamp recording. This concentration is within the
serum therapeutic range used in clinical settings for treat-
ment of epilepsy (10–20 lg/ml) [49]. The inhibition of
neuronal VGSCs, e.g., Nav1.2, by phenytoin is well
established [20]. However, the effect of phenytoin on
Nav1.5-mediated Na
? current in BCa cells has not been
investigated. Consistent with previous reports [12, 13], we
did not detect any voltage-activated Na? currents in
a b
c
e
d
Fig. 1 SCN5A is up-regulated
in breast tumors and associates
with poor prognosis.
a Expression of SCN5A in
invasive breast cancer (IBCa),
ductal carcinoma in situ (DCIS),
invasive ductal breast
carcinoma (IDBCa), or invasive
mixed breast carcinoma
(IMBCa), versus normal breast
in three datasets analyzed in
Oncomine: [41] (n = 59); [42]
(n = 7); and The Cancer
Genome Atlas (TCGA;
n = 371). b Receiver operating
characteristic (ROC) curve
analysis of prediction of
metastasis at five years in [43]
(n = 181). c Comparison of
SCN5A expression between
those with/without recurrence at
five years in [44] (n = 8).
d Comparison of SCN5A
expression between patients
with invasive breast carcinoma
alive or dead at five years in
TCGA dataset (n = 6).
e Kaplan–Meier survival
analysis comparing overall
survival of those with high
versus low SCN5A expression in
Ref. [45] (n = 40). Box plot
dots maximum and minimum
values; whiskers 90th and 10th
percentile values; and
horizontal lines 75th, 50th, and
25th percentile values.
*P \ 0.05; ***P \ 0.001
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weakly metastatic MCF-7 cells (n = 10 cells recorded;
Fig. 4a, upper trace). We therefore focused our electro-
physiological analysis on MDA-MB-231 cells, which
express robust Na? currents [15].
We first studied the tonic block of Na? current, which
arises from low-affinity binding of phenytoin to VGSCs in
their resting state. Following step depolarization of MDA-
MB-231 cells to -10 mV, the VGSCs opened, resulting in a
‘‘transient’’ inward Na? current that decayed toward base-
line within a few milliseconds due to VGSCs rapidly entering
the inactivated state (Fig. 4a, lower trace). The VGSC
inactivation was incomplete, and a small steady-state ‘‘per-
sistent’’ Na? current (approximately 5 % of the transient
peak) continued to flow until the end of the depolarizing step
(Fig. 4a). Perfusion of phenytoin (50 lM) onto cells during
the recording significantly and reversibly reduced the
amplitude of the transient and persistent Na? currents
(Fig. 4a). When cells were depolarized to -10 mV from a
holding potential of -120 mV, the transient current was
inhibited by 43.3 ± 5.4 % (P \ 0.001; Fig. 4b; Table 3).
Similarly, the persistent current (measured as mean inward
current between 45 and 50 ms following depolarization) was
inhibited by 42.4 ± 8.0 % (P \ 0.05; Fig. 4b; Table 3). The
tonic block following depolarization to -10 mV from a less
negative holding potential of -80 mV was considerably
larger: transient current was inhibited by 79.9 ± 2.2 %,
and persistent current was inhibited by 49.1 ± 7.4 %
(P \ 0.001; Fig. 4c; Table 3). Phenytoin also caused a hy-
perpolarizing shift in the voltage-dependence of steady-state
inactivation, shifting the voltage at which half the channels
were inactivated (V1/2) from -79.0 ± 2.0 to -104.4 ±
4.8 mV (P \ 0.001; Fig. 4d; Table 3).
We next studied the use-dependent block of Na? current
by phenytoin. Repeated depolarization from -120 to
0 mV, at a frequency of 50 Hz, caused a rapid decline in
current amplitude that reached a plateau of 84.2 % of ini-
tial current after the fourth pulse (Fig. 4e). In the presence
of phenytoin, the decline in current reached a plateau of
80.6 % after the fifth pulse (Fig. 4e). Thus, phenytoin
Table 1 Relationship between ER/PR/HER2 status and SCN5A
expression
Relationship Fold change in
SCN5A expression
P Dataset
ER? versus ER- 0.93 0.60 TCGA
ER? versus ER- 1.21 0.97 [41]
PR? versus PR- 0.99 0.80 TCGA
PR? versus PR- 1.08 0.95 [41]
HER2? versus HER2- 1.18 0.06 TCGA
HER2? versus HER2- 0.83 0.82 [41]
Triple negative versus other 1.04 0.73 TCGA
Triple negative versus other 1.21 0.95 [41]
ER estrogen receptor, PR progesterone receptor, HER2 human
epidermal growth factor 2, TCGA The Cancer Genome Atlas
Data are shown for datasets in which SCN5A is elevated in BCa
samples ([41] and TCGA dataset). ER/PR/HER2 status is not avail-
able for [42]
SCN5A
a
b
Fig. 2 SCN5A expression as an outlier associates with metastasis.
a SCN5A (normalized expression units) is shown for all profiled
samples in [70]. Horizontal line 95th percentile cut-off, above which
extend the top 5th percentile samples. b Percentage of those that
developed metastasis within five years is shown for the 10 % most
highly expressing, and bottom 90 % of samples in [43]. *P \ 0.05
(n = 181)
Table 2 Cancer outlier profile analysis (COPA) of SCN5A expres-
sion in BCa
Gene rank Percentile COPA score Dataset
93 (in top 2 %) 75 23.8 [69]
223 (in top 2 %) 95 5.8 [70]
440 (in top 9 %) 95 43.2 [69]
483 (in top 10 %) 90 31.6 [69]
657 (in top 8 %) 95 3.6 [71]
791 (in top 6 %) 75 1.3 [70]
792 (in top 5 %) 90 3.9 [72]
1011 (in top 7 %) 95 5.2 [72]
1065 (in top 6 %) 75 2.7 [73]
1112 (in top 7 %) 95 12.7 [73]
1286 (in top 9 %) 90 2.9 [70]
SCN5A expression is ranked against other outliers in the dataset at the
given percentile (75th, 90th, 95th), according to COPA score. Higher
rank and COPA score indicate a more significant outlier profile [31]
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caused a small increase in the use-dependent rundown of
Na? current in MDA-MB-231 cells.
Phenytoin caused a tonic inhibition of transient and
persistent Na? current in MDA-MB-231 cells, which was
larger at more depolarized holding potentials. This
dependence of tonic block on holding potential has been
reported previously, e.g., [20, 50], and is due to phenytoin
having a higher affinity for channels in the inactivated than
the resting state. Consistent with previous reports, the
resting membrane potential of MDA-MB-231 cells was
-20.3 ± 0.9 mV (n = 5) [12]. At this voltage, the
majority of VGSCs are likely to be in the inactivated state,
thus phenytoin would likely be a highly potent blocker of
the remaining persistent Na? current.
Phenytoin inhibits migration and invasion of BCa cells
The VGSC blocker TTX inhibits detachment, migration, gal-
vanotaxis, and invasion of MDA-MB-231 cells [12–15]. TTX
has no effect on these behaviors in cell lines that do not express
VGSC-mediated Na? currents, including MCF-7 cells [12, 13].
We therefore hypothesized that phenytoin would inhibit
migration and invasion of MDA-MB-231 cells, but not MCF-7
cells. We first tested whether phenytoin was cytotoxic.
Fig. 3 Subcellular distribution of voltage-gated Na? channel a and
b1 subunits. a MCF-7 and MDA-MB-231 cells labeled with pan-
VGSC a subunit and b1 antibodies (magenta and green, respectively),
phalloidin to label actin cytoskeleton (red), and DAPI to label nucleus
(blue). b MCF-7 and MDA-MB-231 cells labeled with pan-VGSC
a subunit antibody (magenta) and GM130 antibody (Golgi marker;
green), phalloidin (red), and DAPI (blue). Arrows indicate co-expres-
sion of a and b1 at the cell edge. Arrowheads indicate perinuclear
expression of a and b1, colocalizing with GM130 (b). Intensity
profiles (normalized to maximum signal) for pan-VGSC a subunit and
phalloidin across representative lamellipodia indicated by lines in
(a) are shown for MCF-7 (c) and MDA-MB-231 (d) cells. e VGSC
a subunit intensity in lamellipodia relative to internal signal, for
MCF-7 and MDA-MB-231 cells. Data are mean ± SEM (n C 36).
***P \ 0.001
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Incubation with phenytoin (5–200 lM) for 24 h had no effect
on viability of MCF-7 or MDA-MB-231 cells in a trypan blue
exclusion assay (P = 0.93 and 0.67, respectively; Fig. 5a).
Similarly, phenytoin had no effect on the proliferation of MCF-
7 or MDA-MB-231 cells (P = 0.98 and 0.73, respectively;
Fig. 5b).
We next tested the effect of phenytoin on migration in a
wound heal assay. Phenytoin (5–200 lM; 24 h) had no
effect on the migration of MCF-7 cells (P = 0.41), but
significantly reduced the migration of MDA-MB-231 cells
by 27.3 ± 1.9 % at 50 lM, and 37.2 ± 1.8 % at 200 lM
(P \ 0.001; Fig. 6a, b). Similarly, phenytoin (50 lM;
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Fig. 4 Effects of phenytoin on Na? current. a Typical whole-cell
recordings from MCF-7 cell (top) and MDA-MB-231 cell (bottom)
following depolarization to -10 mV (black arrows) from a holding
potential of -80 mV. Na? current in MDA-MB-231 cell is shown in
control solution, following perfusion with 50 lM phenytoin, and drug
washout. b Tonic block (%) of transient and persistent current in
MDA-MB-231 cells (activated by depolarization to -10 mV from a
holding potential of -120 mV) following perfusion with 50 lM
phenytoin, and drug washout. c Tonic block (%) of transient and
persistent current in MDA-MB-231 cells (activated by depolarization
to -10 mV from a holding potential of -80 mV) following perfusion
with 50 lM phenytoin, and drug washout. d Steady-state inactivation
in MDA-MB-231 cells. Normalized current, elicited by 60 ms test
pulses at -10 mV following 250 ms conditioning pulses between
-120 and -10 mV, applied from a holding potential of -80 mV,
plotted as a function of the prepulse voltage for cells in control and
following perfusion with 50 lM phenytoin. Data are fit with
Boltzmann functions. e Use-dependent block of transient current in
MDA-MB-231 cells, elicited by 50 Hz pulse trains to 0 mV, applied
from a holding potential of -120 mV, normalized to the current
evoked by the first pulse plotted as a function of the pulse number for
cells in control and following perfusion with 50 lM phenytoin. Data
are fit with single exponential functions, which are significantly
different between control and phenytoin (P \ 0.001). Data are
mean ± SEM (n C 7). *P \ 0.05; ***P \ 0.001
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48 h) had no effect on the invasion of MCF-7 cells
(P = 0.99), but significantly reduced the invasion of MDA-
MB-231 cells by 27.1 ± 3.1 % (P \ 0.05; Fig. 6c). In
conclusion, phenytoin significantly inhibited the migration
and invasion of MDA-MB-231 cells, which express func-
tional VGSCs.
Discussion
The expression of VGSCs in electrically excitable cells,
and their importance as therapeutic targets in excitability-
related disorders, e.g., epilepsy, has been long established
[19]. However, it is only more recently that their impor-
tance in cancer has begun to be identified [8]. SCN5A/
Nav1.5 is expressed, predominantly in its neonatal splice
form, in MDA-MB-231 cells, which are triple negative for
ER/PR/HER2 [12]. Neonatal Nav1.5 is expressed in cells of
epithelial origin in BCa biopsies, but is absent in normal
breast [12]. We found several studies in Oncomine in
which SCN5A was up-regulated in BCa compared with
normal tissue. However, there was no relationship between
SCN5A expression and ER/PR/HER2 status in these data-
sets. SCN5A expression has been reported in other cancers,
including lymphoma [51], neuroblastoma [52], colorectal
[53], lung [24], and ovarian cancers [54]. In addition, other
VGSC subtypes have been reported in melanoma [55],
mesothelioma [56], cervical [57, 58], lung [24], ovarian
[54], and prostate cancers [59, 60].
SCN5A was more highly expressed in samples from
patients who had a recurrence, metastasis, or died within
5 years. SCN5A expression as an outlier also associated with
metastasis. These findings agree with a previous report cor-
relating neonatal SCN5A variant mRNA in BCa biopsies
with lymph node metastasis [12]. The microarray probes
used in the studies in Oncomine do not distinguish between
neonatal and adult SCN5A splice variants. However, the
neonatal splice variant is predominant in MDA-MB-231
cells and in BCa biopsies in which both variants were studied
[12, 15]. In conclusion, our data support the notion that
SCN5A is up-regulated in BCa, and may be a marker for poor
prognosis.
Blocking Na? current carried by Nav1.5 in MDA-
MB-231 cells with TTX, siRNA, or antibodies, inhibits
migration, galvanotaxis, and invasion, and enhances adhe-
sion [12–15]. Similarly, blocking Na? current suppresses
these behaviors in cell lines from other cancers (reviewed in
[8]). VGSCs are expressed at lamellipodia of MDA-MB-231
and MCF-7 cells, consistent with VGSCs functioning within
these regions to regulate adhesion, migration, and invasion.
Importantly, the lamellipodial/cell body a subunit expres-
sion ratio is higher in MDA-MB-231 cells than MCF-7 cells,
consistent with a subunits regulating migration and invasion
in the former, rather than the latter cell line. It is possible that
MCF-7 cells also express other VGSC a subunit variants that
have impaired conduction [48]. Thus, in addition to being a
Table 3 Effect of phenytoin on Na? current parameters in MDA-
MB-231 cells
Parameter Control Phenytoin (50 lM)
Tonic block, Vm = -120 mV
Transient (%) – 43.3 ± 5.4
Persistent (%) – 42.4 ± 8.0
Tonic block, Vm = -80 mV
Transient (%) – 79.9 ± 2.2
Persistent (%) – 49.1 ± 7.4
Inactivation V1/2 (mV) -79.0 ± 2.0 -104.4 ± 4.8
Inactivation k (mV) -8.3 ± 1.0 -10.9 ± 1.9
Vm membrane potential, V1/2 half inactivation voltage, k slope factor
a
b
Fig. 5 Effect of phenytoin on viability and proliferation. a Viability
(%) of MCF-7 and MDA-MB-231 cells following treatment with
phenytoin (5, 50, 200 lM) or vehicle for 24 h, normalized to control
(n = 60). b Proliferation of MCF-7 and MDA-MB-231 cells follow-
ing treatment with phenytoin (5, 50, 200 lM) or vehicle for 24 h,
normalized to control (n C 9). Data are mean ± SEM
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marker for metastatic BCa, Nav1.5 may be a useful therapeutic
target for slowing disease progression and/or metastasis.
A number of VGSC-targeting drugs are used to treat
other diseases, e.g., epilepsy [19]. Several of these drugs,
including phenytoin, bind preferentially to VGSCs that are
inactivated [20, 50]. VGSCs typically inactivate within a
few milliseconds of opening following depolarization, and
remain in that state until the membrane repolarizes [5].
Several subtypes, including Nav1.5, do not inactivate
completely, and continue to carry a small steady-state
persistent Na? current at depolarized potentials [61, 62].
Cancer cells typically have a more depolarized membrane
potential than normal epithelial cells, or terminally differ-
entiated excitable cells, e.g., neurons [63]. Thus, it is the
persistent component of Na? current that is likely to be
predominant in BCa cells, potentiating invasion and
migration. Phenytoin significantly inhibited both transient
and persistent Na? currents in MDA-MB-231 cells.
Importantly, the tonic block was greater at more depolar-
ized holding voltages, suggesting that phenytoin may be a
highly effective VGSC blocker in depolarized cancer cells.
This is the first report of phenytoin inhibiting Na? current
in cancer cells, and agrees with the effect of this drug on
VGSCs in other cells, e.g., [20, 50].
Our electrophysiological data suggest that phenytoin
may be a useful therapeutic agent for blocking Na? current
in BCa cells. Na? current enhances invasion by promoting
cysteine cathepsin activity in caveolae [16, 17], and Nav1.5
has been proposed to be a key regulator of invasion-con-
trolling genes [53]. We found that phenytoin significantly
inhibited migration and invasion in MDA-MB-231 cells
expressing Na? currents by *30 %. This is equivalent to
the effect of blocking VGSCs using TTX, siRNA, or
antibodies, reported previously [12, 13, 15]. Phenytoin had
no effect on the migration or invasion of MCF-7 cells,
which do not express Na? currents. Phenytoin also had no
effect on the proliferation of either cell line, consistent with
previous reports indicating that VGSCs regulate cell
migration and invasion, but not proliferation [8]. Phenytoin
has been shown to inhibit HERG channels at significantly
higher concentrations (IC50 for HERG [ 300 lM, vs. IC50
for VGSC *10 lM) [19, 21]. MCF-7 cells express out-
ward K? currents, although the channel has not yet been
identified [12, 17]. In contrast, MDA-MB-231 cells do not
express any voltage-dependent K? (e.g., HERG) currents
[12, 17]. Together, these data suggest that phenytoin (50,
200 lM) inhibited VGSC-dependent migration and inva-
sion in MDA-MB-231 cells by suppressing Na? current,
rather than inhibiting another target, e.g., HERG channels.
The concentration of phenytoin that inhibits Na? cur-
rent, migration, and invasion (50 lM) is within the serum
therapeutic range used in clinical settings for treatment of
epilepsy [49]. Our data suggest that repurposing phenytoin
Fig. 6 Effect of phenytoin on migration and invasion. a Representa-
tive images of MCF-7 and MDA-MB-231 cells in a wound healing
assay at 0 h, and 24 h following treatment with phenytoin (5, 50,
200 lM) or vehicle. b Migration of MCF-7 and MDA-MB-231 cells
treated with phenytoin (5, 50, 200 lM) or vehicle for 24 h in wound
healing assay, normalized to control (n = 135 measurements per
condition). c Invasion of MCF-7 and MDA-MB-231 cells ± phenyt-
oin (50 lM) for 48 h, normalized to control (n = 9). Data are
mean ± SEM. **P \ 0.01; ***P \ 0.001
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to BCa warrants further study as a potential new treatment.
However, it is possible that the effect of phenytoin on BCa
in vivo may be more complex, given that VGSCs are
expressed on a multitude of cell types, and this would
require further investigation [8, 64, 65]. Another FDA-
approved VGSC-blocking drug, riluzole, which also
inhibits metabotropic glutamate receptors, has shown
promise in treating melanomas, and reduces BCa tumor
volume in mice [66, 67]. Use of VGSC-blocking local
anesthetics during radical prostatectomy surgery is asso-
ciated with substantially reduced recurrence and metastasis
[68]. In conclusion, a growing body of evidence supports
the notion that VGSCs may be useful therapeutic targets in
cancer.
Our data support the hypothesis that SCN5A is up-reg-
ulated in BCa, and plays a role in metastasis. In agreement
with previous reports [12, 53], SCN5A expression may be
an important event in progression toward metastasis.
Together with other studies [12, 13, 15, 53], this study
suggests that Nav1.5-mediated Na
? current favors an
invasive phenotype. We therefore propose that using
VGSC-blocking drugs, in particular those that target per-
sistent Na? current, should be considered for further study
as a potential strategy to improve patient outcomes in
metastatic BCa.
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